Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 275, Issue 1 44-1, 1998, Pages

  Burrell, Louise M ^a   Phillips, Paddy A ^a   Risvanis, John ^a   Chan, Robert K ^a   Aldred, Kathryn L ^a   Johnston, Colin I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Echocardiography; Myocardial infarction; Receptors; Survival

Indexed keywords

ANGIOTENSIN I; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; MOZAVAPTAN; RENIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIURETIC THERAPY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART INFARCTION; HEART VENTRICLE REMODELING; HEART WEIGHT; LUNG WEIGHT; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; URINE OSMOLALITY; URINE VOLUME; WATER RETENTION;

EID: 33750856291     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1998.275.1.h176     Document Type: Article

References (39)

1. Abraham, W., R. Oren, A. Robertson, and R. Schrier. Effects of an oral, nonpeptide, selective V2 receptor AVP antagonist in human heart failure (Abstract). Nephrology 3: S15, 1997.
2. Brooks, D. P., M. Valente, G. Petrone, P. D. Depalma, M. Sbacchi, and G. D. Clarke. Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs. J. Pharmacol. Exp. Ther. 280: 1176-1183, 1997.
3. Burrell, L., R. Chan, P. Phillips, P. Calafiore, A. Tonkin, and C. Johnston. Validation of an echocardiographic assessment of cardiac function following moderate size myocardial infarction in the rat. Clin. Exp. Pharmacol. Physiol. 23: 570-572, 1996.
4. Burrell, L. M., J. Palmer, J. A. Charlton, T. Thomas, and P. H. Baylis. A new radioimmunoassay for human atrial natriuretic peptide and its physiological validation. J. Immunoassay 11: 159-175, 1990.
5. Burrell, L. M., P. A. Phillips, J. Risvanis, K. L. Aldred, A. M. Hutchins, and C. I. Johnston. Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Hypertension 26: 828-834, 1995.
6. Burrell, L. M., P. A. Phillips, J. M. Stephenson, J. Risvanis, K. A. Rolls, and C. I. Johnston. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 23: 737-743, 1994.
7. Cody, R. J. Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. J. Am. Coll. Cardiol. 22, 4 Suppl. A: 165A-171A, 1993.
8. Creager, M. A., D. P. Faxon, S. S. Cutler, O. Kohlmann, T. J. Ryan, and H. Gavras. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J. Am. Coll. Cardiol. 7: 758-765, 1986.
9. Duncan, A.-M., L. M. Burrell, A. Kladis, and D. J. Campbell. Effect of angiotensin converting enzyme inhibition on angiotensin and bradykinin peptides in myocardial infarction. J. Cardiovasc. Pharmacol. 28: 746-754, 1996.
10. Duncan, A.-M., L. M. Burrell, A. Kladis, and D. J. Campbell. Angiotensin and bradykinin peptides in rats with myocardial infarction. J. Card. Fail. 3: 41-52, 1997.
11. Fujisawa, G., S. Ishikawa, Y. Tsuboi, K. Okada, and T. Saito. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int. 44: 19-23, 1993.
12. Furukawa, Y., S. Takayama, L. M. Ren, S. Sawaki, Y. Inoue, and S. Chiba. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations. J. Pharmacol. Exp. Ther. 263: 627-631, 1992.
13. Gaudron, P., M. Blumrich, and G. Ertl. Aggravation of left ventricular dilatation and reduction of survival by a calcium channel blocker in rats with chronic myocardial infarction. Am. Heart J. 125: 1226-1233, 1993.
14. Goldsmith, S. R., G. S. Francis, A. W. Cowley, Jr., I. F. Goldenberg, and J. N. Cohn. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J. Am. Coll. Cardiol. 8: 779-783, 1986.
15. Goldsmith, S. R., G. S. Francis, A. W. Cowley, Jr., T. B. Levine, and J. N. Cohn. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. 1: 1385-1390, 1983.
16. Hodsman, G. P., M. Kohzuki, L. G. Howes, E. Sumithran, K. Tsunoda, and C. I. Johnston. Neurohumoral responses to chronic myocardial infarction in rats. Circulation 78: 376-381, 1988.
17. Johnston, C. I. Vasopressin in circulatory control and hypertension. J. Hypertens. 3: 557-569, 1985.
18. Johnston, C. I., F. A. O. Mendelsohn, and D. J. Casely. Evaluation of renin and angiotensin assays and their clinical applications. Med. J. Aust. 1: 126-128, 1971.
19. Hinter, L., S. Caltabiano, and W. Hofrman. Anomalous antidiuretic activity of antidiuretic hormone antagonists. Biochem. Pharmacol. 45: 1731-1737, 1993.
20. Kohzuki, M., M. Kanazawa, K. Yoshida, E. Tsutsumi, M. Yasujima, K. Abe, C. I. Johnston, and T. Sato. Cardiomegaly and vasoactive hormones in rats with chronic myocardial infarction: long-term effects of chlorothiazide. Clin. Sci. (Colch.) 90: 31-36, 1996.
21. Martin, P. Y., and R. W. Schrier. Sodium and water retention in heart failure: pathogenesis and treatment. Kidney Int. Suppl. 59: S57-S61, 1997.
22. Mulinari, R. A., I. Gavras, Y. X. Wang, R. Franco, and H. Gavras. Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. Circulation 81: 308-311, 1990.
23. Naitoh, M., L. M. Burrell, J. Risvanis, C. L. Johnston, and J. Power. Comparison of chronic V2R blockade and ACE inhibition in CHF in sheep (Abstract). Nephrology 3: S52, 1997.
24. Naitoh, M., H. Suzuki, M. Murakami, A. Matsumoto, K. Arakawa, A. Ichihara, H. Nakamoto, K. Oka, Y. Yamamura, and T. Saruta. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol. 267 (Heart Circ. Physiol. 36): H2245-H2254, 1994.
25. Nicod, P., B. Waeber, J. P. Bussien, J. J. Goy, G. Turini, J. Nussberger, K. G. Hofbauer, and H. R. Brunner. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. J Am. J. Cardiol. 55: 1043-1047, 1985.
26. Nishikimi, T., Y. Kawano, Y. Saito, and H. Matsuoka. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J. Cardiovasc. Pharmacol. 27: 275-282, 1996.
27. Ohnishi, A., Y. Orita, R. Okahara, H. Fujihara, T. Inoue, Y. Yamamura, Y. Yabuuchi, and T. Tanaka. Potent aquaretic agent. A novel nonpeptide selective vasopressin V2 antagonist (OPC-31260) in men. J. Clin. Invest. 92: 2653-2659, 1993.
28. Ohnishi, A., Y. Orita, N. Takagi, T. Fujita, T. Toyoki, Y. Ihara, Y. Yamamura, T. Inoue, and T. Tanaka. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J. Pharmacol. Exp. Ther. 272: 546-551, 1995.
29. Pfeffer, J. M., M. A. Pfeffer, and E. Braunwald. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation 75, 1 Pt 2: I149-I155, 1987.
30. Pfeffer, M., E. Braunwald, L. Moye, L. Basta, E. J. Brown, T. Cuddy, B. Davis, E. Geltman, S. Goldman, and G. Flaker. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327: 669-677, 1992.
31. Pullan, P. T. C., C. I. Johnston, W. P. Anderson, and P. I. Korner. The role of vasopressin in blood pressure control and in experimental hypertension. Clin. Sci. Mol. Med. 5: 251S-254S, 1978.
32. Sahn, D., A. DeMaria, J. Kisslo, and A. Weyman. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-1083, 1978.
33. Shimizu, K. Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans. Kidney Int. 48: 220-226, 1995.
34. Tsuboi, Y., S. Ishikawa, G. Fujisawa, K. Okada, and T. Saito. In vivo diuretic effect of a new non-peptide arginine vasopressin antagonist, OPC-31260, in conscious rats. J. Endocrinol. 143: 227-234, 1994.
35. Tsuboi, Y., S. Ishikawa, G. Fujisawa, K. Okada, and T. Saito. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int. 46: 237-244, 1994.
36. Tsunoda, K., G. P. Hodsman, E. Sumithran, and C. I. Johnston. Atrial natriuretic peptide in chronic heart failure in the rat: a correlation with ventricular dysfunction. Circ. Res. 59: 256-261, 1986.
37. Wang, Y. X., R. Franco, I. Gavras, and H. Gavras. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction. J. Lab. Clin. Med. 117: 313-318, 1991.
38. Yamamoto, K., U. Ikeda, K. Okada, T. Saito, Y. Kawahara, M. Okuda, M. Yokoyama, and K. Shimada. Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes. Hypertension 30: 1112-1120, 1997.
39. Yamamura, Y., H. Ogawa, H. Yamashita, T. Chihara, H. Miyamoto, S. Nakamura, T. Onogawa, T. Yamashita, T. Hosokawa, and T. Mori. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 105: 787-791, 1992.